GENE ONLINE|News &
Opinion
Blog

2018-03-06|

6 March, 2014: First time Scientist gene-editing Immune Cells Successful, open a new treatment possibility for AIDS

by GeneOnline
Share To

A research team from the Perelman School of Medicine, University of Pennsylvania, enrolled 12 patients in an uncontrolled study of a single dose of ZFN-modified autologous CD4 T cells. The patients had the chronic aviremic HIV infection while they were receiving highly active antiretroviral therapy. After the infusion of 10 billion autologous CD4 T cells, the blood level of HIV DNA decreased in most patients. This study was a milestone for gene-editing technology application on fatal disease treatment.

Reference
http://www.nejm.org/doi/full/10.1056/NEJMoa1300662

Image Source
https://en.wikipedia.org/wiki/HIV

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Bacteriophage Characteristics Could Provide the Key to Tackling Viruses
2022-11-02
Gilead Touts Long-Term Efficacy And Safety Data For HIV Drug
2022-10-26
Merck’s Phase 2 HIV Treatment Study Resumes with Phase 3 Program Announcement
2022-09-20
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!